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789Randomized clinical trials have demonstrated that
implantable cardioverter-deﬁbrillators (ICD) prolong life in
patients at high risk of sudden cardiac death (SCD) (1).
Over the past decade, ICD implantation rates have
increased. However, despite the proven beneﬁts of these
devices, their implantation is associated with a risk of
procedure-related adverse events that are associated with
prolonged hospital length of stay (2), higher cost (2), and
decreased 6-month survival (3). To collect information
about characteristics and outcomes of patients undergoing
ICD implantation in routine clinical practice, the ICD
Registry was developed by the American College of Cardi-
ology NCDR (National Cardiovascular Data Registry) in
partnership with the Heart Rhythm Society (4). One goal of
the registry is to provide information about adverse events
that can be used for quality improvement efforts (5).
See page 797
Each participating hospital whose submission passes data
quality thresholds receives quarterly feedback on quality met-
rics, including the incidence of adverse events at their hospital
compared with average performance for all participating hos-
pitals. To date, these reports have not adjusted for differences in
patient or procedural characteristics between participating
hospitals. As a result, currently reported variations in crude
event ratesmay in part reﬂect differences in casemix rather than
hospital performance. To address this limitation, we developed
a riskmodel for adverse events (complications ormortality) that
uses ICDRegistry data to calculate hospitals’ risk standardized
complication rates. Hospitals can use this information to
identify whether their performance is above or below average
and to target quality improvement efforts accordingly. In
addition, the model provides a mechanism for providing indi-
vidualized estimates of procedural risk that can be used to
facilitate shared decision making and to determine the appro-
priate level of care following the procedure.
Methods
Data source. Details of the ICD Registry have been previ-
ously described (4). In brief, the registry currently collects data
on over 90% of ICD placed in the United States (6). Infor-
mation about patients undergoing ICD implantation is
collected using standardized deﬁnitions and submitted by
participating hospitals to the ICD Registry via a secure web-
site. Submitted data then undergo quality checks and are
returned to hospitals for cleaning and resubmission if they do
not pass criteria for completeness (7). For the current study,
we used version 2 data, which were collected beginning in
April 1, 2010. Full elements are available on the NCDR
website (5). For our study group, we included all patients
undergoing a new ICD implantation or an ICD replacement
from April 1, 2010 to December 31, 2011 with the exclusion
of those undergoing epicardial lead placement, lead-only
procedures, and any procedure involving lead extraction.Selection of candidate variables.
To determine the optimal out-
comes to include in the risk model,
a working group was established
(S.A., J.C., J.D., M.K., M.M.,
E.P., M.R.) and it met on a
bimonthly basis. The group re-
viewed all complications collected
by the registry and excluded those
whose occurrence was either ex-
ceedingly rare (venous obstruction:
0.03%, conduction block: 0.02%, peripheral embolus: 0.01%,
valve injury: <0.01%, peripheral nerve injury: <0.01%), or
unlikely to be related to the procedure (drug reaction: 0.05%).
On the basis of the working group’s consensus, the ﬁnal primary
outcome (any adverse event) consisted of a composite measure
of procedure-related complications including any of the
following: cardiac arrest; cardiac perforation; coronary venous
dissection; hemothorax; device-related infection; lead dis-
lodgement; myocardial infarction; pericardial tamponade;
pneumothorax; stroke/transient ischemic attack; urgent cardiac
procedure; hematoma; or set screw problem. Given its im-
portance, mortality was included in the composite endpoint
with the understanding that it may not always have been
directly attributable to the procedure.
For candidate covariates in risk model development, we
initially screened all relevant demographic, clinical, and
procedural characteristics available from the registry. The
working group determined that certain covariates would be
excluded for the following reasons: potential collinearity
with other covariates (diastolic blood pressure, ischemic
heart disease); low frequency (post-transplant, syndrome
with high risk of SCD); clinical judgment of factors deemed
unlikely to inﬂuence complication risk (PR-interval dura-
tion, family history of SCD); subjective reporting (life
expectancy <1 year); as well as variables that could reﬂect
potential disparities in care (race, insurance status). To assess
the potential impact of excluding race from the risk model,
we performed a sensitivity analysis that included race and
found that it did not signiﬁcantly change our results.
Statistical analysis. We present continuous variables as
mean  SD and categorical variables as percentages. For
continuous variables, we examined their distribution and
established clinically relevant cut points reﬂecting their as-
sociation with adverse events. Bivariate comparisons of pa-
tients with and without the primary outcome were performed
using the t test (continuous variables) and the chi-square test
(categorical variables).
Data were missing for <1% of variables except for cardiac
arrest (1.5%), laboratory values (glomerular ﬁltration rate:
1.3%, potassium: 1.4%, sodium: 1.6%, blood urea nitrogen:
1.8%, hemoglobin: 2.3%), and left ventricular ejection
fraction (9.0%). For cardiac arrest, we assumed “not present”
if missing. We imputed glomerular ﬁltration rate to the sex-
speciﬁc median consistent with previous NCDR models (8).
Missing data for left ventricular ejection fraction were
Table 1 Characteristics of Patients With and Without Complications
Complication or In-Hospital Death*
p ValueNo (n ¼ 236,244) Yes (n ¼ 4,388)
Admission characteristics
Age, yrs 67.3  13.2 68.4  13.2 <0.0001
Female 64,205 (27.2) 1459 (33.9) <0.0001
Reason for admission <0.0001
Admitted for procedure 173,561 (73.6) 2,304 (52.7)
Heart failure 19,325 (8.2) 731 (16.7)
Other 42,819 (18.2) 1,336 (30.6)
History of heart failure <0.0001
No 136,357 (57.9) 2,218 (50.6)
YesdHF hospitalization within 6 months 36,639 (15.6) 1,112 (25.4)
Yesdno HF hospitalization within 6 months 62,456 (26.5) 1,050 (24.0)
NYHA functional class <0.0001
I/II 121,884 (51.8) 1,489 (34.6)
III 106,680 (45.4) 2,652 (58.6)
IV 6,665 (2.8) 319 (7.3)
Nonischemic dilated cardiomyopathy 79,587 (33.8) 1,682 (38.4) <0.0001
Syncope 38,212 (16.2) 799 (18.2) 0.0003
Atrial ﬁbrillation/ﬂutter 84,992 (36.0) 1,748 (39.8) <0.0001
Ventricular tachycardia 90,193 (38.2) 1,611 (36.8) 0.0483
Cardiac arrest 22,004 (9.3) 515 (11.7) <0.0001
Previous ICD 96,587 (40.9) 943 (21.5) <0.0001
Previous pacemaker 25,322 (10.7) 562 (12.8) <0.0001
Prior myocardial infarction 119,904 (50.8) 2,103 (48.0) 0.0002
Prior PCI 76,604 (32.5) 1405 (32.0) 0.5542
Prior CABG 77,955 (33.0) 1266 (28.9) <0.0001
Primary valvular heart disease 28,610 (12.1) 674 (15.4) <0.0001
Cerebrovascular disease 37,324 (15.8) 806 (18.4) <0.0001
Diabetes 89,436 (37.8) 1,734 (39.6) 0.0233
Currently on dialysis 6,373 (2.7) 243 (5.5) <0.0001
Chronic lung disease 50,683 (21.5) 1,180 (26.9) <0.0001
Hypertension 184,876 (78.3) 3,503 (79.9) 0.0139
Sleep apnea 28,526 (12.1) 550 (12.6) <0.0001
Continued on the next page
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790imputed to the median, and we added a dummy variable as
missing indicator. Missing continuous laboratory values
were imputed to the median.
We then randomly split our sample into derivation and
validation cohorts (70% derivation/30% validation). In the
derivation cohort, we developed a risk model using logistic
regression with backward selection of candidate variables.
We generated odds ratios (OR) with 95% conﬁdence in-
tervals (CI) to determine the strength of association for
covariates that remained signiﬁcant. We then evaluated
model discrimination in the derivation and validation co-
horts using C-statistics. For validation, we applied coefﬁ-
cients of the models from the derivation cohort to the
validation cohort assessing the predicted versus observed rate
of adverse events within deciles of predicted adverse event
risk. We also generated C-statistics for primary versus sec-
ondary ICD in the derivation cohort, and in 3 other clini-
cally meaningful subgroups: 1) ﬁrst-time ICD implantations
(in patients without previous ICD or pacemaker); 2)previous ICD excluding those undergoing generator re-
placements; and 3) cardiac resynchronization therapy with
deﬁbrillation (CRT-D) devices.
For the purposes of clinical application, we developed a
parsimonious risk score that could be used to calculate pa-
tient risk at the bedside. To develop the score, we removed
variables from the full model until the adjusted R2 of the
parsimonious model was 95% of the full model. The per-
formance of the parsimonious model was evaluated in the
derivation and validation cohorts by C-statistics and vali-
dation plots. We also evaluated model discrimination and
calibration in 3 clinically meaningful subgroups (as with the
full model): ﬁrst-time ICD recipients, previous ICD
excluding those undergoing generator replacements, and
CRT-D devices. We based the risk score system on the beta
coefﬁcients for the risk factors in the parsimonious model.
Categorical variables were assigned numeric values propor-
tional to their associated beta coefﬁcients. Continuous var-
iables of the risk score model were classiﬁed into several
Table 1 Continued
Complication or In-Hospital Death*
p ValueNo (n ¼ 236,244) Yes (n ¼ 4,388)
Diagnostics
Cardiac rhythm <0.0001
Sinus 153,546 (65.2) 2,866 (65.5)
Atrial ﬁbrillation/ﬂutter 34,027 (14.5) 789 (18.0)
Paced 44,698 (19.0) 586 (13.4)
Atrioventricular blockdsecond- and third-degree 1,606 (0.7) 77 (1.8)
Other 1,487 (0.6) 57 (1.3)
Abnormal conduction <0.0001
No 110,141 (46.8) 1,556 (35.6)
Yesdleft bundle branch block 52,957 (22.5) 1,417 (32.4)
Yesdother 72,114 (30.7) 1,402 (32.0)
Procedure type <0.0001
Initial implantation 139,630 (59.2) 3,445 (78.5)
Generator replacementdend of battery life 80,790 (34.2) 463 (10.6)
Generator replacementdinfection 1,943 (0.8) 83 (1.9)
Generator replacementddevice relocation 379 (0.2) 11 (0.3)
Generator replacementdupgrade 10,151 (4.3) 312 (7.1)
Generator replacementdmalfunction 912 (0.4) 20 (0.5)
Generator changedother 2,134 (0.9) 52 (1.2)
ICD type <0.0001
Single-chamber 45,312 (19.2) 514 (11.7)
Dual-chamber 90,585 (38.4) 1,459 (33.3)
CRT-D 99,875 (42.4) 2,404 (54.9)
Body mass index, kg/m2 29.8  13.5 29.3  14.5 0.0182
Left ventricular ejection fractiony 30.4  12.7 27.7  11.5 <0.0001
Systolic blood pressure, mm Hg 131.6  22.7 129.2  23.3 <0.0001
Hemoglobin, g/dl 13.1  2.0 12.5  2.1 <0.0001
Glomerular ﬁltration rate 65.1  25.7 60.3  27.5 <0.0001
Blood urea nitrogen, mg/dl 23.7  13.0 27.5  16.9 <0.0001
Sodium, mEq/l <0.0001
<135 22,316 (9.6) 683 (15.7)
135–145 207,895 (89.4) 3,608 (83.0)
>145 2,305 (1.0) 58 (1.3)
Potassium, mEq/l 0.0009
<3.5 7,829 (3.4) 189 (4.3)
3.5–4.5 167,388 (71.9) 3,128 (71.9)
>4.5 57,627 (24.7) 1,031 (23.7)
Values are mean  SD or n (%). *Complications include any of the following: cardiac arrest; cardiac perforation; coronary venous dissection; hemothorax;
device-related infection; lead dislodgement; myocardial infarction; pericardial tamponade; pneumothorax; stroke/transient ischemic attack; urgent cardiac
procedure; hematoma; or set screw problem. yEjection fraction data were missing for 8.8% of patients.
CABG ¼ coronary artery bypass graft; CRT-D ¼ cardiac resynchronization therapy with deﬁbrillation; HF ¼ heart failure; ICD ¼ implantable cardioverter-
deﬁbrillator; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention.
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791categories and these categories were assigned numeric values
proportional to the product of the beta coefﬁcient and the
distance from the base category to these categories (9). For
each patient, the ICD complication risk score was calculated
as the simple arithmetic sum of point values assigned to each
risk factor. We calculated the adverse event rates observed
within the population based on risk score values by intervals
of 10 in both the derivation and validation cohorts to eval-
uate the performance of risk scores.
Data from derivation and validation cohorts were then
combined to calculate risk-standardized complication rates.
We used hierarchical logistic regression models to account forclustering of patient admissions within hospitals (10,11). The
assumption with this approach is that after adjusting for pa-
tient risk factors, the remaining variation is attributable to
hospital-level factors. The predicted number of complications
at each hospital was estimated given its patient mix and using
its own hospital-speciﬁc intercept, and the expected number
of complications in each hospital was estimated using its pa-
tientmix and average hospital-speciﬁc intercept on the basis of
all hospitals in the sample. The risk-standardized complica-
tion rate for each hospital was computed by the ratio of
number of predicted complications to the number of expected
complications, multiplied by the unadjusted overall
Table 3 Risk Model for Complications After ICD Implantation
OR (95% CI) p Value
Age, 10-yr increase 1.086 (1.049–1.126) <0.0001
Sex
Male Reference d
Female 1.289 (1.187–1.400 ) <0.0001
Reason for admission
Admitted for procedure Reference d
Heart failure 1.450 (1.299–1.620 ) <0.0001
Other 1.571 (1.430–1.725 ) <0.0001
NYHA class
I/II Reference d
III 1.346 (1.231–1.473) <0.0001
IV 2.007 (1.709–2.357) <0.0001
Nonischemic dilated cardiomyopathy 1.117 (1.017–1.227) 0.0206
Cardiac arrest
No Reference d
Yesdbradycardic 1.512 (1.132–2.019) 0.0052
Yesdtachycardic 1.209 (1.062– 1.376) 0.0040
Prior PCI 1.098 (1.008–1.197) 0.0324
No prior CABG 1.225 (1.117–1.344) <0.0001
Cerebrovascular disease 1.131 (1.027–1.244) 0.0120
Diabetes 0.913 (0.845–0.987) 0.0218
Current dialysis 1.557 (1.298–1.868) <0.0001
Chronic lung disease 1.211 (1.115–1.315) <0.0001
Cardiac rhythm 0.0167
Sinus Reference d
Atrial ﬁbrillation/ﬂutter 1.118 (1.010–1.237) 0.0317
Paced 1.029 (0.907–1.167) 0.6615
AV blockdsecond or third degree 1.352 (0.992–1.842) 0.0564
Other 1.399 (1.051–1.863) 0.0215
Abnormal conduction
No Reference d
YesdLBBB 1.256 (1.129d1.396) <0.0001
Yesdother 1.228 (1.117d1.350) <0.0001
Continued in the next column
Table 2
Prevalence of Complications and Mortality Among
Study Sample (N ¼ 240,632)
Complications
Lead dislodgement 1,580 (0.66)
Hematoma 723 (0.30)
Pneumothorax 573 (0.24)
Cardiac arrest 482 (0.20)
Coronary venous dissection 230 (0.10)
Device-related infection 194 (0.08)
Pericardial tamponade 147 (0.06)
Cardiac perforation 107 (0.04)
Stroke or transient ischemic attack 106 (0.04)
Hemothorax 60 (0.02)
Set screw problem 67 (0.03)
Urgent cardiac procedure 38 (0.02)
Myocardial infarction 41 (0.02)
Mortality 637 (0.26)
Complications or mortality 4,388 (1.82)
Values are n (%).
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792complication rate. We computed a 95% interval estimate of
the risk-standardized complication rate to characterize the
level of uncertainty around the point estimate using boot-
strapping simulation. The risk-standardized complication
rates and associated interval estimates can be used to charac-
terize and compare hospitals’ performance with the registry
average. As an illustrative example, we used the risk-
standardized complication rate and interval estimates to
characterize hospital performance as better than registry
average, no different than the registry average, and worse
than registry average.
A p value of <0.05 was considered statistically signiﬁcant
for all tests. Analyses were performed using SAS (version
9.2, SAS institute, Cary, North Carolina).Results
Patient characteristics. During the study period, 263,284
procedures were performed. Procedures involving lead-
only placement (n ¼ 9,855, 3.7%), epicardial lead place-
ment (n ¼ 5,677, 2.2%), and lead extraction (n ¼ 7,120,
2.9%) were excluded, leaving an analytic sample of
240,632 procedures. Of these, the majority (59.5%) rep-
resented ﬁrst-time ICD implantations. Over three-quarters
of implantations (76.6%) were for primary prevention in-
dications. Mean age of the study group was 67.3 years, andTable 3 Continued
OR (95% CI) p Value
Procedure type
Initial implant 3.573 (3.132–4.075) <0.0001
Generator replacementd
end of battery life
Reference d
Generator replacementdinfection 5.631 (4.188–7.572) <0.0001
Generator replacementd
device relocation
5.980 (3.135–11.408) <0.0001
Generator replacementd
upgrade
3.162 (2.626–3.809) <0.0001
Generator
replacementdmalfunction
3.735 (2.168–6.434) <0.0001
Generator replacementdother 3.984 (2.830–5.610) <0.0001
ICD type
Single-chamber Reference d
Dual-chamber 1.450 (1.282–1.641) <0.0001
CRT-D 1.727 (1.508–1.977) <0.0001
Sodium
<135 1.292 (1.164–1.433) <0.0001
135–145 Reference
>145 1.213 (0.874–1.685) 0.2482
Systolic blood pressure,
1-point increase
0.980 (0.964–0.997) 0.0184
Hemoglobin, 5 g/dl increase) 0.755 (0.680–0.838) <0.0001
Glomerular ﬁltration rate,
10-U increase
1.029 (1.007–1.051) 0.0079
BUN, 10 mg/dl increase 1.123 (1.089–1.158) <0.0001
Full model (odds ratios from derivation cohort). C-statistic ¼ 0.724.
AV ¼ atrioventricular; BUN ¼ blood urea nitrogen; CI ¼ conﬁdence interval; LBBB ¼ left bundle
branch block; OR ¼ odds ratio; other abbreviations as in Table 1.
Table 4
Parsimonious Risk Scoring System for Complications
After ICD Implantation
Beta
Coefﬁcient
Reference
Value Points
Sex
Male 0 0
Female 0.2307 2
Reason for admission
Admitted for procedure 0 0
Heart failure 0.3846 4
Other 0.5006 5
NYHA functional class
I/II 0 0
III 0.2990 3
IV 0.7102 7
No prior CABG 0.2293 2
Current dialysis 0.3149 3
Chronic lung disease 0.2018 2
Abnormal conduction
No 0 0
YesdLBBB 0.2376 2
Yesdother 0.2296 2
Procedure type
Initial implant 1.2462 13
Generator
replacementd
end of battery life
0 0
Generator
replacementdinfection
1.6851 17
Generator
replacementd
device relocation
1.7789 18
Generator
replacementdupgrade
1.1349 12
Generator
replacementdmalfunction
1.2964 13
Generator
replacementdother
1.3568 14
ICD type
Single-chamber 0 0
Dual-chamber 0.3737 4
CRT-D 0.5745 6
Sodium*
<135 0.2600 3
135–145 135–145 0
>145 0.2274 2
Hemoglobin* 0.3029
<12 3
12–14 2
>14 >14 0
BUN* 0.0971
<20 <20 0
20–40 2
>40 4
Risk score based on parsimonious model. C-statistic for risk score ¼ 0.721. *Sodium analyzed as
3-level categorical variable (nonlinear relationship); hemoglobin and BUN analyzed as continuous
variables (linear relationship).
Abbreviations as in Tables 1 and 3.
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79327.3% were women. The most common medical conditions
were hypertension (78.3%), previous myocardial infarction
(50.7%), heart failure (42.4%), diabetes (37.9%), and
chronic lung disease (21.6%). The most common device
type was CRT-D (42.5%), followed by dual-chamber ICD
(38.3%), then single-chamber ICD (19.0%).
Complications. Overall, 4,388 patients (1.8%) experienced
an adverse event. The characteristics of patients with and
without adverse events are shown in Table 1. On average,
patients who experienced an adverse event were older (68.4
vs. 67.3 years, p < 0.0001), more often female (33.2%
vs. 27.2%, p < 0.0001), and less likely to have “ICD im-
plantation” listed as the primary reason for admission
(52.7% vs. 73.6%, p < 0.0001). Patients with adverse
events were also more likely to have experienced a hospital
stay for heart failure within the last 6 months (25.4% vs.
15.6%, p < 0.0001).
The individual in-hospital adverse events (complications
or mortality) are listed in Table 2. The most common
events were lead dislodgement (n ¼ 1,580, 0.66%),
hematoma (n ¼ 723, 0.30%), and pneumothorax (n ¼ 573,
0.24%). In-hospital death occurred in 637 patients (0.26%).
Risk model. The full model for adverse events after ICD
implantation included 21 variables (Table 3). The greatest
strength of association was seen with procedure type.
Patients undergoing an initial ICD implantation were over
3 times as likely to experience complications as those un-
dergoing a generator replacement for end of battery life
(OR: 3.57, 95% CI: 3.13 to 4.08), and placement of either
a CRT-D or dual-chamber device were more likely to
experience complications compared with single-chamber
devices (CRT-D vs. single-chamber: OR: 1.73, 95% CI:
1.51 to 1.98; dual-chamber vs. single-chamber: OR: 1.45,
95% CI: 1.28 to 1.64). Increasing severity of heart failure
was also strongly associated with complications (New York
Heart Association functional class IV vs. class I/II: OR:
2.01, 95% CI: 1.71 to 2.36). The model demonstrated good
discrimination in both the derivation and validation cohorts
(C-statistics: 0.724 and 0.722 for derivation and validation
cohorts, respectively), and for primary and secondary pre-
vention subgroups in the derivation cohort (C-statistics:
0.713 and 0.763, respectively).
Among ﬁrst-time ICD implantation patients (no previous
ICD or pacemaker, n ¼ 128,749) and patients with a previous
ICD, excluding those undergoing generator replacements
(n ¼ 30,630), model discrimination was lower (C-statistics:
0.666 and 0.639, respectively). Among the subgroup of pa-
tients receiving CRT-D devices (n ¼ 102,279), the C-statistic
was 0.703.
Parsimonious model. The parsimonious risk model
retained 12 characteristics from the full model (Table 4).
The parsimonious model had similar discrimination
(C-statistics: 0.721 and 0.718 for derivation and validation
cohorts, respectively). A point system was developed on the
basis of regression coefﬁcients. The highest number of
points was attributable to procedure type; for example, apatient received 18 points for undergoing device relocation
(compared with 0 points for an end-of-battery-life generator
replacement). The distribution of risk scores among the
Figure 1 Frequency of Risk Scores Among the Study Sample
Each patient in the study sample was assigned a numeric score on the basis of a
parsimonious risk model that included 12 patient and procedural characteristics
that independently predicted procedure-related adverse events. There was a
relatively even distribution of scores across a wide range of values.
Figure 2
Risk of Complications for In-Hospital Adverse
Events Based on Risk Scoring System
The risk of procedure-related adverse events (complications or in-hospital death)
increased in a roughly linear matter as the numeric risk score increased.
Figure 3 Distribution of RSCR Among Hospitals
In general, there was clustering around the median risk-standardized complication
rate (RSCR), which was 1.77% (interquartile range: 1.54%, 2.14%). Compared with
the registry average, 54 hospitals (3.8%) were worse than expected and 15
hospitals (1.1%) were better than expected.
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794study group is shown in Figure 1. On the basis of this
distribution, patients with a risk score of 10 or less were at
very low risk of complications (0.3%). In contrast, patients
with a risk score of 30 or more had a considerably increased
risk of complications (4.2%) (Fig. 2).
Hospital distribution. The distribution of risk-standardized
complication rates among participating hospitals (n ¼ 1,428)
is shown in Figure 3. The median risk-standardized com-
plication rate was 1.77 (IQR: 1.54 to 2.14, 95% CI: 1.16 to
3.15, respectively). Compared with the registry average, 54
hospitals (3.8%) were worse than expected, and 15 hospitals
(1.1%) were better than expected.
Discussion
We developed a risk model to predict in-hospital adverse
events after ICD implantation using clinical characteristics
that are readily available at the time of procedure. Our efforts
had 2 purposes. First, the risk model can be used to
benchmark hospital complication rates and therefore can be
a useful tool in quality improvement efforts. Second, the risk
score derived from the model can be used to facilitate shared
decision making with patients by incorporating a subjects
expected risks of ICD implantation.
Our model provides adverse event rates that are risk
standardized (risk-standardized complication rates) that
we believe will have higher clinical signiﬁcance for par-
ticipating sites. To date, hospitals submitting data to the
ICD Registry have received quarterly feedback reports
listing their crude ICD complication rates compared
with average rates for participating hospitals, and this
approach has failed to account for differences in the
case mix. Sites may therefore dismiss higher crudecomplication rates as due to patient complexity rather
than physician or system-wide factors that may be tar-
geted for quality improvement. The use of risk-
standardized complication rates in future reports should
have higher face validity and allow a more compelling
argument for internal evaluation of the quality of care among
sites that are low performing.
The strongest risk factors for adverse events in our model
were procedure type (any procedure other than simple
generator replacement), ICD type (other than single lead),
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admission. Using our risk model, a patient with all 5
risk factors (e.g., undergoing initial device implantation,
dual-chamber device, New York Heart Association func-
tional class IV, blood urea nitrogen ¼ 45, admission for
primary reason other than device placement) would have an
expected complication risk of at least 4%. Conversely, other
patients (e.g., elective admission for a single-lead ICD with
mildly symptomatic heart failure and normal renal func-
tion) would have an expected complication risk of <1%.
Our model may therefore be used for informed discussions
between clinicians and patients about the individualized
risk of ICD implantation. In addition, the model may
potentially be used to identify particularly low-risk patients
who may require less intensive post-procedure monitoring
(e.g., same-day discharge).
Several other ﬁndings are worthy of note. Our observed
adverse event rate (1.8%) was lower than in most previous
studies, including those using ICD Registry data (12–14).
For example, a study of 268,701 ICD Registry patients
undergoing procedures from 2006 to 2008 found a com-
plication rate of 3.2% (12). Older studies generally re-
ported even higher in-hospital complication ratesdup to
10% in several reports (13,14). The low rate of adverse
events in our study sample may represent differences be-
tween our datasets and others (i.e., some previous studies
using claims data rather than ICD Registry data), or a
secular trend toward improved in-hospital outcomes
among ICD recipients over time. We do not think our low
adverse event rate would negatively affect the performance
of our risk model; however, because data are self-reported
from sites, with the potential for under-reporting of
complications at certain hospitals, we believe it is prema-
ture for our risk-standardized complication rates to be
used for public reporting. However, the information can be
used by hospitals to promote internal quality improvement
efforts to improve the outcomes associated with their ICD
implantations.
An additional ﬁnding of interest is that patient age did
not enter into our parsimonious risk model, as its strength of
association with adverse events was weak. On the basis of
our investigation and others (12,13,15), age does not appear
to be a strong predictor of in-hospital adverse events.
Therefore, older patients with few comorbidities may be
expected to have reasonably good post-procedural outcomes.
Study limitations. Our results were limited to in-hospital
adverse events, and therefore our model is unable to
predict risk of post-discharge complications (such as de-
vice infection) that may require rehospitalization. Also, as
some hospitals do not submit data to the registry, or
submit poor quality data, the in-hospital adverse event rate
in practice may be higher than was reported in our study
sample, and there may be risk factors for adverse events
that we were unable to identify. In addition, our model
only provides information about the expected risk of de-
vice implantation, not potential beneﬁts. Nevertheless, webelieve this information will prove useful in promoting
shared decision making. Another potential barrier to
widespread use of the risk score is that there are 12
covariates in our parsimonious model, which is more than
several other risk scores. Nevertheless, these characteristics
are generally readily available on all patients undergoing
ICD implantation. Furthermore, the growth of electronic
medical records may facilitate the calculation of a risk
score by identifying risk factors in an automated fashion.
Finally, given that data are self-reported, enhanced efforts
to verify complication rates with external chart audits of
participating hospitals may improve the validity of our
observations.
Conclusions
We developed a simple model that predicts risk for in-
hospital adverse events among patients undergoing ICD
placement. This can be used for both shared decision
making and to benchmark hospital performance for quality
improvement efforts.
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